Aphasia Clinical Trial
Official title:
A Novel Treatment for Aphasia and Apraxia of Speech: Measurement of Outcomes
Verified date | March 2019 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In order to determine if speech-language therapy has positive effect, reliable measurement
tools are required to document outcomes. Currently, there is very limited information
concerning the measurement of changes in speech production as a result of treatment for
acquired apraxia of speech and aphasia. This study will obtain information concerning the
reliability of several speech production measures over time. Thirty persons with chronic
aphasia and apraxia of speech will be asked to provide speech samples in response to commonly
used assessment tools on three sampling occasions so that the stability of measurements may
be examined.
After establishment of appropriate outcome measures, a small, pilot treatment study will be
conducted with four participants. The participants will receive a new treatment for aphasia
and acquired apraxia of speech and outcomes will be measured relative to speech and language
production.
Status | Completed |
Enrollment | 4 |
Est. completion date | December 22, 2017 |
Est. primary completion date | December 30, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Veterans or non Veterans with aphasia and apraxia of speech who reside in the Salt Lake City region (commutable), - 12 months or more post stroke or other focal brain injury, no other neurological conditions, - native English speakers, hearing adequate for experimental task (e.g., pass puretone screening at 35dB at 500, 1K, 2K Hz), - non linguistic cognition within normal limits Exclusion Criteria: - less than 12 months post stroke, - insufficient hearing, insufficient non linguistic cognitive skills, - neurological conditions other than stroke, - more than one stroke or brain injury - unable to attend treatment in the Salt Lake City vicinity |
Country | Name | City | State |
---|---|---|---|
United States | VA Salt Lake City Health Care System, Salt Lake City, UT | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Bailey DJ, Blomgren M, DeLong C, Berggren K, Wambaugh JL. Quantification and Systematic Characterization of Stuttering-Like Disfluencies in Acquired Apraxia of Speech. Am J Speech Lang Pathol. 2017 Jun 22;26(2S):641-648. doi: 10.1044/2017_AJSLP-16-0108. — View Citation
Wambaugh JL, Wright S, Mauszycki SC, Nessler C, Bailey D. Combined aphasia and apraxia of speech treatment (CAAST): Systematic replications in the development of a novel treatment. Int J Speech Lang Pathol. 2018 Apr;20(2):247-261. doi: 10.1080/17549507.20 — View Citation
Wambaugh JL, Wright S, Nessler C, Mauszycki SC. Combined Aphasia and Apraxia of Speech Treatment (CAAST): effects of a novel therapy. J Speech Lang Hear Res. 2014 Dec;57(6):2191-207. doi: 10.1044/2014_JSLHR-L-14-0004. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Language Content Production for Treated Stimuli: Effect Sizes (Magnitude of Change From Baseline to Follow-up) | Correct Information Units (CIUs) is a measure of the amount of relevant content produced in connected language tallied according to operationalized criteria. CIU is not a test or scale - it is a measure that is applied to language samples - in this case, description of treated pictures. Participants described experimental pictures, responses were transcribed and CIUs counted. CIUs can range from 0 to an unlimited maximum. Effect sizes (ESs) were calculated as an indication of the magnitude of change in number of CIUs produced (pre treatment to post treatment. ESs can range from negative (poorer performance post-treatment) to positive values (better performance post-treatment), with larger positive values reflecting greater gains. Benchmarks are as follows: >11.14 = large, 11.13 - 6.56 = medium, 6.55 - 3.88 = small, <3.88 = negligible. Small to large ESs indicate production of measurably more CIUs in picture descriptions post-treatment. Larger the ES, the greater the change. | Following completion of treatment at 6 weeks post | |
Primary | Change in Production of Language Content for Untreated Sets - Generalization Measured in Effect Sizes | Correct Information Units (CIUs) is a measure of the amount of relevant content produced in connected language tallied according to operationalized criteria. CIU is not a test or scale - it is a measure that is applied to language samples - in this case, description of untreated pictures. Participants described experimental pictures, responses were transcribed and CIUs counted. CIUs can range from 0 to an unlimited maximum. Effect sizes (ESs) were calculated as an indication of the magnitude of change in number of CIUs produced (pre treatment to post treatment. ESs can range from negative (poorer performance post-treatment) to positive values (better performance post-treatment), with larger positive values reflecting greater gains. Benchmarks are as follows: >9.53 = large, 9.52 - 5.52 = medium, 6.55 - 3.29 = small, <3.29 = negligible. Small to large ESs indicate production of measurably more CIUs in picture descriptions post-treatment. Larger the ES, the greater the change. | baseline (prior to treatment) through follow-up at 6 weeks post treatment | |
Secondary | Changes in Speech Intelligibility on the Assessment of Intelligibility of Dysarthric Speech | Speech intelligibility (understandability of speech) was measured by having participants produce 50 words from the Assessment of Intelligibility of Dysarthric Speech (ASSIDS) Two speech-language (blinded) scored pre and post treatment ASSIDS samples. The percentage of words correctly understood was calculated for each participant. The ASSIDS is not a scale - it is a procedure for calculating intelligibility. Speech intelligibility can range from 0% to 100% intelligible (no words understood to all words understood). The higher the percentage, the better the speech is understood by the listener. Change in percent words intelligible has the potential to be a negative (reflecting a poor outcome of less intelligible speech) or positive (reflecting a good outcome of more intelligible speech). The maximum possible amount of gain in intelligibility for these 4 participants, based on their pretreatment performance, ranged from +2% to +25%. | pre and post treatment - prior to the start of treatment and at 6 weeks following the completion of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03622411 -
Tablet-based Aphasia Therapy in the Chronic Phase
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Recruiting |
NCT03929432 -
Treatment Outcomes With tDCS in Post-Stroke Aphasia
|
N/A | |
Completed |
NCT03662295 -
Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
|
||
Completed |
NCT03679637 -
Tablet-based Aphasia Therapy in the Acute Phase After Stroke
|
N/A | |
Completed |
NCT03228264 -
A Trial Investigating Telerehabilitation as an add-on to Face-to-face Speech and Language Therapy in Post-stroke Aphasia.
|
N/A | |
Completed |
NCT03550092 -
Analysis of Brain Activity to Uncover Brain-behavior Relationships Related to Therapy Outcomes in Aphasia
|
N/A | |
Suspended |
NCT04290988 -
Circuitry Assessment and Reinforcement Training Effects on Recovery
|
N/A | |
Recruiting |
NCT05969548 -
pBFS-guided cTBS at Different Doses for Aphasia After Stroke
|
N/A | |
Recruiting |
NCT04138940 -
Modulating Intensity and Dosage of Aphasia Scripts
|
N/A | |
Terminated |
NCT02249819 -
Evaluating Anodal tDCS Preceding Aphasia Therapy
|
Phase 1/Phase 2 | |
Completed |
NCT01654029 -
Patient Centred Communication Intervention
|
N/A | |
Completed |
NCT00843427 -
fMRI of Language Recovery Following Stroke in Adults
|
N/A | |
Active, not recruiting |
NCT00227461 -
Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.
|
Phase 1 | |
Completed |
NCT03773419 -
Improving Electronic Written Communication in Aphasia
|
N/A | |
Not yet recruiting |
NCT04142866 -
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
|
N/A | |
Suspended |
NCT04048668 -
tDCS to Treat Subacute Aphasia
|
N/A | |
Recruiting |
NCT04081207 -
Using Augmentative & Alternative Communication to Promote Language Recovery for People With Post-Stroke Aphasia
|
N/A | |
Completed |
NCT02226796 -
Transcranial Direct Stimulation (tDCS) and Behavioral Intervention in Aphasia
|
N/A | |
Completed |
NCT01163461 -
Phonomotor Treatment of Word Retrieval Deficits in Individuals With Aphasia
|
N/A |